Mersana Therapeutics, Inc. (NASDAQ:MRSN) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$40m beat estimates by a substantial 30 ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.

Date/Time: Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com.

Mersana Therapeutics stock opened at $0.48 on Monday. The firm has a market cap of $59.30 million, a price-to-earnings ratio of -0.79 and a beta of 1.39. Mersana Therapeutics has a 1 year low of ...

Mersana Therapeutics, Inc., a pharmaceutical company based in Cambridge, Massachusetts, has received a notification from The Nasdaq Stock Market LLC regarding non-compliance with the exchange's ...

Mersana's Q4 2024 EPS of -0.11 exceeded expectations, improving from the forecast of -0.15. Revenue for the quarter was $16.36 million, significantly above the forecast. The company ended 2024 ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.

March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

“We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics (MRSN). “These ...